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Background: To address knowledge gaps regarding natural health product (NHP) usage in mental health
populations, we examined their use in adults with mood disorders, and explored the potential for adverse events.
Methods: Food and NHP intake was obtained from 97 adults with mood disorders. NHP data was used to compare
prevalence with population norms (British Columbia Nutrition Survey; BCNS). Bivariate and regression analyses
examined factors associated with NHP use. Assessment of potential adverse effects of NHP use was based on
comparing nutrient intakes from food plus supplements with the Dietary Reference Intakes and by reviewing
databases for reported adverse health effects.
Results: Two-thirds (66%; 95% CI 56 to 75) were taking at least one NHP; 58% (95% CI 47 to 68) were taking NHPs
in combination with psychiatric medications. The proportion of each type of NHP used was generally higher than
the BCNS (range of p’s < 0.05 to 0.0001). When intakes from food and NHP sources were combined, a small
proportion exceeded any Lowest-Observed-Adverse-Effect-Levels: only for niacin (n = 17) and magnesium (n = 6),
two nutrients for which the potential for adverse effects is minimal. Conversely, about 38% (95% CI 28 to 49) of the
sample were taking a non-nutrient based NHP for which previous adverse events had been documented.
Conclusions: The prevalent use of NHPs in this population suggests that health care providers need to be
knowledgeable about their characteristics. The efficacy and safety of NHPs in relation to mental health warrants
further investigation.
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People with mental health conditions often use a variety
of therapeutic alternatives which are not necessarily
disclosed to their primary health care provider. Remedies
used may include natural health products (NHPs), defined
as agents that include constituents such as vitamins and
minerals, herbs, homeopathic medicines, traditional medi-
cines, probiotics, and other products like amino acids and
essential fatty acids [1].* Correspondence: karen.davison@ubc.ca
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distribution, and reproduction in any mediumNational surveys of general populations have found that
NHP use is increasing around the world [2-5], but few
studies have examined individuals with mental health
conditions. Available data suggest that NHP use tends
to be higher in those with anxiety and depressive disor-
ders [6-11]. From a public health perspective, there is
some concern that NHPs may interact with conventional
therapies. For example, studies have reported that St. John’s
wort combined with trazodone, sertraline, or nefazodone
may cause serotonin syndrome [12]. Reporting the po-
tential for adverse health-related events such as these
has gained increased attention globally as the informa-
tion serves as a means to prevent harm to individuals
and help formulate recommendations for health systemsCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ficial effects of NHPs including lowered requirement doses
of medications [14-17]. In either case, it would be useful
to know more about NHP use in people with mental
health conditions. This analysis examined characteristics
of NHP use including potential for adverse events in
adults with mood disorders.
Methods
Subjects, settings and procedures
Data from a cross-sectional nutrition survey of adults
(> 18 years; n = 97) that were randomly selected from
the Mood Disorders Association of British Columbia
(MDABC) membership list and resided in the lower
mainland of British Columbia (n = 1400) was used; the
list was provided to researchers by the MDABC. Sample
size verification was obtained using one-sample inference
for a binomial proportion [18] with estimates of NHP use
at 60% in the study population and general population
use being 46% [19], alpha of 0.05, and statistical power
of 80%.
Individuals (n = 146) randomly selected from the MDABC
membership list were first sent a letter inviting their par-
ticipation in the study. Subsequent to the invitation letter,
a research staff member phoned the potential participant
to ask if the research coordinator could contact them to
discuss the project. Ten attempts were made to contact
the potential participant if there continued to be no answer.
Then the file was closed. For those who agreed to partici-
pate, the research coordinator reviewed procedures of the
study over the phone including instructions of how to
complete their food records that were mailed out to them.
Overall, 97% of the 146 names drawn for the study were
resolved; that is, they were located and contacted to
participate. Of those, a range of 124 to 129 individuals
were considered in-scope or eligible based on informa-
tion available. Individuals were considered out-of-scope
or not eligible if they were dead, had moved out of the
area, or exhibited at least one of the exclusion criteria
(e.g., pregnant, lactating, living in an institution). Of
those contacted and eligible, 3% refused to participate
in the study and 2% did not show up for their appoint-
ment (based on the upper bound of 129 eligible).
The study protocol including details about verification
of mood disorder diagnosis (i.e., bipolar I, bipolar II, and
depressive disorder) using the Structured Clinical Interview
for DSM-IV Axis I Disorders [20] and Global Assessment
of Functioning (GAF) [21], exclusion criteria (i.e., presence
of another condition impacting mental health), current
symptoms of depression and mania based on the Hamilton
Depression Scale (Ham-D) [22], and Young Mania Rating
Scale (YMRS) [23], and collection of nutrient intake data
are detailed elsewhere [24]. Of those that participated in
the screening to assess eligibility, two were found to beineligible. The study’s protocol including consent pro-
cedures were approved by the University of Calgary’s
Conjoint Health Research Ethics Board. The consent
procedures involved first mailing the study’s consent
forms to those who agreed to participate, so that they
could review it at their leisure. Then when the participants
attended their appointment, they first reviewed the con-
sent forms with the research coordinator or clinical inter-
viewer and signed the form once they fully understood
all aspects of the study (i.e., all information would be
held in strict confidence) and were agreeable to partici-
pating. Honourariums were provided to cover expenses
(e.g., taxis, buses, gas, parking) and time associated with
completing a 3-day food record and attending the office
interview (about 180 minutes total).
As part of the face-to-face survey interviews conducted
at the MDABC office, respondents brought all medications
and natural health products (e.g., vitamin, mineral, herbal,
botanical, and homeopathic preparations) they were tak-
ing. Details of NHP use based on type, composition (e.g.,
ingredients and amounts recorded from the labels), and
frequency (e.g., taken daily, monthly) were taken by a
trained interviewer.Statistical analysis
Nutrient and NHP intake data were collected using the
standardized procedures of the British Columbia Nutrition
Survey (BCNS) that included nutrient analysis of 3-day
food records using ESHA software and the Canadian
Nutrient File. Full information about the BCNS, nutrient
analyses methods, and quality control procedures [25] are
detailed elsewhere.
Comparisons of NHP use (e.g., prevalence) were made
with the BCNS (population norm) and associated factors
such as socio-demographic (i.e., sex, age, relationship
status, education, income) and clinical (i.e., medication
use, depressive versus bipolar disorder, GAF, years since
diagnosis, BMI, psychiatric symptom scores) characteris-
tics were analysed using binomial tests of two proportions,
Fisher Exact statistics, Student t-tests, Mann–Whitney
tests and correlations where appropriate. Variables that
were found to be significant based on the bivariate analysis
were then analyzed in the logistic (i.e., NHP use as dichot-
omous dependent variable) and multiple regression (i.e.,
number of NHPs used as continuous dependent variable)
models to examine factors associated with NHP use. No
more than four variables were placed into a model at
one time and all models were evaluated to ensure they
met statistical test assumptions (e.g., normality, homo-
scedasticity) and goodness of fit (e.g., graphical depictions
of the residuals, Hosmer and Lemeshow’s goodness-of-fit
test). All statistical analyses were conducted using Stata
7.0 software.
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recorded for each participant, expressed as a daily amount
and added to the usual intake obtained from food sources
alone. For example, vitamin C from food sources averaged
over 3 days was added to vitamin C from supplements
expressed as a daily amount based on previous month’s
use. Nutrient intakes (from food and NHPs combined)
were compared to the Tolerable Upper Intake Levels (UL)
of the Dietary Reference Intakes (DRIs), where applicable,
to estimate prevalence of excess intakes. The ULs repre-
sent a daily nutrient amount for almost all healthy individ-
uals where risk of adverse effects increases as intake levels
exceed the standard [26]. For those intakes exceeding
the ULs, the amounts were then compared to the Lowest
Observed Adverse Effect Levels (LOAELs) of the DRIs,
when available. The LOAEL is the lowest amount for
which an adverse effect has been reported [26].
For NHPs without DRI comparison data, safety of
use was examined by conducting detailed electronic
searches of all products taken by participants for any
reported adverse events. The databases searched in-
cluded MEDLINE, EMBASE, PsychINFO, the Cochrane
Library, CINAHL, NAPRALERT, MedEffect™ Canada,
International Pharmaceutical Abstracts, CISCOM, and
HerbMed. Search terms included common and scien-
tific names, as well as synonyms for the NHPs and
their primary active constituents. Adverse events in-
cluded those reported from individual NHPs as well as
any potential interactions that may have occurred from
concurrent NHP use and with medications that partici-
pants were taking. We refer to this as the potential for
adverse events previously defined as an unsafe state,
not currently an event, but likely to lead to an event if
it persists without intervention [27].
Results
Sample
The response rate was about 75% (97/129), calculated
with the assumption that all the unresolved cases were
in-scope (eligible). Those who did not want to partici-
pate in the study were asked a set of demographic health
behaviour questions including their marital status, edu-
cation level, use of vitamin and mineral supplements,
type of bread and milk they consumed, and whether they
smoked; no significant group differences were found be-
tween study participants and the non-responders based
on these variables. The first author verified with the
MDABC that the sample reflected the demographics (e.g.,
gender, age range) of their membership.
Most of the sample was female (n = 69; 71%; 95% CI
62% to 80%), had government-defined low income levels
(n = 47; 49%; 95% CI 39% to 58%), had educational attain-
ment levels less than a university degree (n = 76; 78.4%;
95% CI 70% to 87%), tended to carry excess weight (BMI >25; n = 65; 67%; 95% CI 58% to 76%), had bipolar I or II
disorder (60%; 95% CI 50% to 70%), and were considered
to be high functioning based on mean GAF scores (62.7 ±
14.7) and median YMRS (Median = 3; 25th%ile = 1; 75th%
ile = 5) and Ham-D scores (Median = 9.7, 25th%ile = 3.75;
75th%ile = 14.75).
Prevalence and characteristics of NHP use
A total of 267 different NHPs were used in this sample.
The proportion of the respondents taking at least one
NHP was 66% (95% CI 56% to 75%). Fifty-eight percent
of the sample (95% CI 47% to 68%) were taking NHPs
in combination with their psychiatric medications that
mainly included typical and atypical antipsychotics, anti-
depressants, and mood stabilizers; 8% (95% CI 4% to 16%)
were taking these products without prescription medica-
tions. Of those who were taking NHPs, the average (mean)
number of products used was 3 (range of 1 to 21; 95% CI
4 to 10). More than half of the sample were taking single
or combination vitamin and mineral therapies, herbs and
natural products and other nutrients such as glucosamine,
amino acids, essential fatty acids from oils, and lactic
acid bacteria (Table 1). Males had higher intakes of most
single and combination preparations of vitamins, replace-
ment preparations, and other nutrients (Table 1) (range
of p’s < 0.05 to 0.0001). Comparisons of NHP use based
on bivariate and regression statistical analyses with
sociodemographic (i.e., age, education, income, relation-
ship status) and clinical factors (i.e., psychiatric medica-
tion use, depressive vs. bipolar I and II disorder, GAF,
years since diagnosis of mental health condition, BMI,
depression scores, mania scores) showed no significant
associations.
NHPs and potential for adverse events
When vitamin and mineral intakes from food and sup-
plements were combined and compared to the DRIs, 2%
(95% CI 0.3 to 7) to 8% (95% CI 4 to 16) of the sample
had intakes that exceeded the ULs for 8 nutrients
(Table 2); of these, 19% (95% CI 11 to 28) had niacin in-
takes above the LOAEL of 50 mg, and 6% (95% CI 2 to
13) had magnesium intakes above the LOAEL of
360 mg. In addition to the NHPs that had DRI compari-
son data, 16 other products used by 38% (95% CI 28 to
49) of the total sample were identified that could poten-
tially lead to adverse effects as described in Table 3.
The evidence cited in Table 3 often represents anec-
dotal reports of incidents that ranged from mild
gastrointestinal discomfort to significant clinical events
including worsening of mental symptoms.
Discussion
The results of this analysis indicate that there tends to
be a higher prevalence of NHP use among persons with
Table 1 Proportion taking NHPs in the previous month: comparison by sex and to the British Columbia Nutrition
Survey (BCNS) (total sample = 97)
NHP Males (n = 28)% (95% CI)
Females (n = 69)
% (95% CI)
Total (n = 97)
% (95% CI)
BCNS (n = 1823)
% (95% CI)
Water Soluble Vitamins (Single)
Vitamin B6 or pyridoxine 68 (51 to 85)
*** 14 (6 to 23) 31 (22 to 41) 0a
Vitamin B9 or folic acid 71 (55 to 88)
*** 28 (17 to 38) 40 (30 to 51) 0a
Vitamin C 64 (47 to 82) 67 (56 to 78) 66 (56 to 75)+++ 24 (22 to 26)
Fat Soluble Vitamins (Single)
Vitamin A 25 (9 to 41)* 4 (0 to 9) 10 (5 to 18)+++ 2 (1 to 3)
Vitamin D 61 (43 to 79) 51 (40 to 62) 64 (54 to 79)+++ 1 (0 to 2)
Vitamin E 46 (28 to 65) 46 (35 to 58) 47 (37 to 58)+++ 17 (15 to 19)
Vitamin Combinations
Vitamin B complex (with or without vitamin C) 68 (51 to 85) 49 (37 to 61) 55 (44 to 65)+++ 9 (8 to 10)
Vitamin A and D combination 21 (6 to 37)* 4 (0 to 11) 9 (4 to 17)++ 3 (2 to 4)
Multivitamins 14 (1 to 27) 19 (10 to 28) 18 (11 to 27)+ 9 (8 to 10)
Minerals (Single and Combinations)
Iron preparations 21 (6 to 37) 20 (11 to 30) 34 (25 to 44)+++ 1 (0 to 2)
Singleb and multiple mineralsc 79 (63 to 94) 78 (69 to 87) 78 (69 to 86)+++ 13 (11 to 15)
Vitamin and Mineral Combinations
Vitamins and minerals 61 (43 to 79) 59 (49 to 71) 60 (49 to 70)+++ 31 (29 to 33)
Other NHPs
Enzymes or gastrointestinal productse 46 (28 to 65) 30 (20 to 41) 35 (26 to 45)+++ 6 (5 to 7)d
Replacementf or homeopathic preparationsg 46 (28 to 65) 29 (18 to 37) 34 (25 to 44)+++ 5 (4 to 6)
Herbal and natural productsh 61 (43 to 79) 51 (39 to 63) 54 (43 to 64)+++ 19 (17 to 21)
Other productsi 61 (43 to 79)* 88 (81 to 96) 75 (65 to 83)+++ 20 (18 to 22)
aPyridoxine and folic acid could not be analyzed statistically due to 0% prevalence in the BCNS.
bIncludes chromium, selenium, zinc, and magnesium.
cIncludes calcium plus magnesium; calcium, magnesium plus zinc; mineral combinations including bromide, calcium, silicon, nitrogen, selenium, phosphorous,
iodide, chromium, manganese, titanium, rubidium, cobalt, copper, antimony, molybdenum, strontium, zinc, nickel, tungsten, germanium, scandium, vanadium,
tellurium, tin, lanthanum, yttrium, silver, gallium, bismuth, zirconium, cerium, cesium, gold, beryllium, hafnium, samarium, terbium, europium, gadolinium,
dysprosium, thorium, holmium, lutetium, erbium, ytterbium, neodymium, praseodymium, niobium, tantalum, thallium, rhenium, indium, and palladium.
dBCNS proportion < 1% but rounded to 1%.
eIncludes antacids, adsorbents, laxatives, digestants.
fElectrolyte-type supplements intended to prevent or treat electrolyte imbalances that include sports drinks, over-the-counter powders and tablets, over-
the-counter electrolyte replenishers, oral rehydration formulae, and multiple electrolyte injections. Most preparations contained sodium, potassium magnesium,
and calcium.
gHomeopathic preparations contain medicinal ingredients and are prepared in accordance with the methods outlined in homeopathic pharmacopoeias.
hIncludes herbs, herbal materials, herbal preparations and finished herbal products, that contain as active ingredients parts of plants, or other plant materials,
or combinations.
iIncludes glucosamine, amino acids, evening primrose oil, coenzyme Q10, flax seed oil, lactic acid bacteria.
Significant differences between males and females at *p < 0.05, **p < 0.001, and ***p < 0.0001.
Significant differences between study sample and BCNS at +p < 0.05, ++p < 0.001, and +++p < 0.0001.
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population (i.e., BCNS data). A small proportion of the
sample exceeded levels deemed to be the upper margin
of safety for the general healthy population for 8 nutrients,
none of which represented significant harms. Finally,
about 38% of survey respondents were potentially expos-
ing themselves to adverse reactions associated with their
use of NHPs that did not contain vitamins or minerals.
The use of NHPs appears to be of a similar scale to
that found in other investigations of mental health popu-
lations where reported prevalence ranges from 50 to
80% [4]. The common use of NHPs may be attributable
to many factors that include media interest in the topic,increased availability of various information sources (e.g.,
the Internet), the perceived efficacy and “naturalness” of
the therapies, desire to reduce side effects, and dissatis-
faction with conventional therapies leading to experi-
mentation with different products [102-104]. Unlike other
studies, our results did not indicate differences in NHP
use according to socioeconomic status which is contrary
to the inverse supplement hypothesis [105], which sug-
gests that those in need of more nutrients due to factors
such as disease risk or limited income are usually not the
ones who take supplements. People with mood disorders
may not consider income a barrier if they believe that the
NHPs will alleviate symptoms.
Table 2 Potential adverse events of vitamin and mineral supplement use based on comparison of nutrient levels to Dietary Reference Intakes and database
searches for reported adverse events for individual vitamins and minerals used
Vitamin/mineral ULa % > UL
a
(95% CI) LOAEL
b % > LOAELb
(95% CI)
Effect at the LOAELb
Vitamins and Minerals with ULsa and LOAELsb
Vitamin B3 or niacin - mg 35
c 28 (19 to 38) 50 19 (11 to 28) Vasodilation causing flushing of the skin
Vitamin B6 or pyridoxine - mg 100 8 (4 to 16) – – –
Vitamin B9 or folate - mcg 1000
c 17 (10 to 25) 5000 0% Precipitate or exacerbate neuropathy in vitamin B12 deficient individuals
Vitamin Dd – mcg and Vitamin Ed - mg D: 100; E:
1000e
3 (1 to 9)
D: 50; E: 39,545 and
18,000f
0%
Vitamin D: Hypercalcemia. Vitamin E: Increased tendency to hemorrhage
seen in rats
Calcium - mg 2500 6 (2 to 13) 5000 0% Hypercalcemia, renal insufficiency
Iron - mg 45 7 (3 to 14) – – –
Magnesium - mg 350c; g 6 (2 to 13) 360 6 (2 to 13) Diarrhea
Zinc - mg 40 mg 6 (2 to 13) – – –
Manganesed - mg 11 mg 8 (4 to 16) – – –
Vitamins and Minerals (without ULsa and LOAELsb)
Product names % (95% CI) Adverse Events Reported in the Literatureh
Pantothenic acid, vitamin B5, pantethine, pantothenol, or
D-pantothenate and Potassiumi
37 (28 to 49)
Forms of pantothenic acid: Diarrhea seen with 10 to 20 grams/day of calcium D-pantothenate [28]. Case report of eosinophilic
pleuropericardial effusion in an elderly woman taking 10 mg of biotin and 300 mg of pantothenic acid daily for two months [29].
Nausea and heartburn, have been reported with pantethine [30]
Potassium: Supplementation of potassium only is generally prescribed to treat hypokalemia while preventing hyperkalemia and
medication interactions. Mild effects include nausea, vomiting, abdominal discomfort, and diarrhea [28]
aTolerable Upper Intake Level.
bLowest Observed Adverse Effect Level: The lowest intake (or experimental oral dose) at which an adverse effect has been identified.
cThe UL for niacin, folate, and magnesium apply to synthetic forms obtained from supplements, fortified foods, or a combination of the two.
dNutrient analysis software for food intakes of vitamin E, vitamin D and manganese have less than 50% coverage for nutrient; thus prevalence estimates of nutrient intakes exceeding the UL are conservative.
eThe UL for vitamin E applies to any form of supplemental α-tocopherol, fortified foods, or a combination of the two.
fLOAEL for vitamin E is based on 500 mg/kg of α-tocopherol.
gThe UL for magnesium is based on gastrointestinal effects from consumption of 350 mg or more of the synthetic form.
hBased on database searches of MEDLINE, EMBASE, PsychINFO, the Cochrane Library, CINAHL, NAPRALERT, MedEffect™ Canada, International Pharmaceutical Abstracts, CISCOM, and HerbMed.



























Table 3 Descriptions of potential adverse events for non-nutrient based NHPs used by sample based on database sea h of reported adverse events for
each NHP
NHP used in sample Adverse events reported for that NHP in the literaturea
Cranberry (Vaccinium macrocarpon) More than one litre daily may cause kidney stones [31]. (Note: In this sample, cranb ry pills were used and did not exceed this level)
Dehydroepiandrosterone (DHEA) or 5-Dehydro-epiandrosterone
(5-DHEA)
People with mood disorders may experience mania, irritability, and sexual inappro ateness [32-35]
Devil’s Claw (Harpago-phytum procumbens) Mild gastrointestinal upset, hypotension, diarrhea, loss of taste, anorexia, headache nd tinnitus [32-34]. May interact with warfarin; one
case report of purpura [36]
Dong Quai (Angelica sinensis), Chinese angelica In a cross-sectional survey (n = 1818), one case was identified as a potential signific t interaction between dong quai and
anticoagulant/antiplatelet agents [37]
Echinacea (Echinacea angustifolia, Echinacea pallida, Echinacea
purpurea)
Gastrointestinal upset and rashes; in rare cases, has been associated with allergic re tions that may be severe [38]. May interact with
amoxicillin [39]
Evening Primrose Oil (Oenothera biennis) Case reports of seizures in patients with/without known seizure disorders [40,41]. In ross-sectional survey (n = 1818), two cases of
potential significant interactions with anticoagulant/antiplatelet agents identified [3
Feverfew (Tanacetum parthenium; syn. Chrysanthemum parthenium
(L.) Pers., Pyrethrum parthenium Sm.)
Gastrointestinal upset [42,43], nervousness, insomnia [44], and possible allergic resp ses in those sensitive to chrysanthemums, daisies,
or marigolds. Potential cross-reactivity with other members of the Compositae fam [45]. In cross-sectional survey (n = 1818), two
cases of potential clinically significant interactions with anticoagulant/antiplatelet a nts identified [37].
Flaxseed (common flax, linseed, Linum usitatissimum) Rarely, flaxseed (not oil form) has caused gastrointestinal distress [46-50]. A double ind placebo-controlled trial suggested there may
be increased episodes of mania and hypomania in people with bipolar disorder [4
Garlic (Allium sativum) Breath and body odour, and allergic reactions [51]. Excess use associated with spo neous epidural hematoma [52]. Potential
reactions include bleeding and hypoglycemia (likely not clinically significant) [53]. I cross-sectional survey (n = 1818), 25 cases of
potential clinically significant interactions with anticoagulant/antiplatelet agents id tified [37]
Ginkgo (Ginkgo biloba) Surveillance studies (> 10,000 people), found 1.69% incidence of symptoms such a eadache and gastrointestinal complaints [54].
Bleeding indicated in a few case reports [55]. May cause allergic hypersensitivity, in ding Stevens-Johnson syndrome [56-58]. In cross-
sectional survey of 1818 patients, 20 cases of potential clinically significant interact s with anticoagulant/antiplatelet agents identified
[37]. Infrequent mild gastrointestinal discomfort has been reported when Ginkgo is ken with selective serotonin reuptake inhibitors
(SSRIs) [59]. May interact with thiazides [60,61], and nifedipine [62,63]
Ginseng (American, Asian, Chinese, Korean red; Panax ginseng,
Panax spp. including P. ginseng and P. quinquefolius)
Long-term use of Panax and American ginseng associated with skin rash, itching, d rrhea, sore throat, loss of appetite, excitability,
anxiety, depression, or insomnia [53,64]. Few reports of headache, fever, dizziness/v tigo, blood pressure changes, chest pain, difficult
menstruation, heart palpitations, leg swelling, nausea, vomiting, manic episodes in polar disorder, or Stevens-Johnson syndrome (may
have been due to product contaminants) [53]. High intake of American ginseng m result in hypoglycemia in people with/without
diabetes [65]. May interact with anticoagulants/antiplatelets [66,67], diabetes medic ions [37], digoxin [68], estrogenic agents [69-71],
furosemide [72], monoaminergic agents [73-75], nifedipine [76]
Ginseng (American, Asian, Chinese, Korean red; Panax ginseng,
Panax spp. including P. ginseng and P. quinquefolius)
Long-term use of Panax and American ginseng associated with skin rash, itching, d rrhea, sore throat, loss of appetite, excitability,
anxiety, depression, or insomnia [53,64]. Few reports of headache, fever, dizziness/v tigo, blood pressure changes, chest pain, difficult
menstruation, heart palpitations, leg swelling, nausea, vomiting, manic episodes in polar disorder, or Stevens-Johnson syndrome (may
have been due to product contaminants) [53]. High intake of American ginseng m result in hypoglycemia in people with/without
diabetes [65]. May interact with anticoagulants/antiplatelets [66,67], diabetes medic ions [37], digoxin [68], estrogenic agents [69-71],
furosemide [72], monoaminergic agents [73-75], nifedipine [76]
Melatonin (N-acetyl-5-methoxytryptamine) May worsen depression and irritability. Sedative medications (CNS depressants) and enzodiazepines interact with melatonin [77]
Omega-3 Fatty Acids, Alpha-Linolenic Acid Caution indicated for those with diabetes as may increase blood glucose, at risk of leeding, or with high LDL levels [78-85]. May

























































Table 3 Descriptions of potential adverse events for non-nutrient based NHPs used by sample based on database search of reported adverse events for
each NHP (Continued)
Valerian (Valeriana officinalis) Mild impairments in concentration, processing, fatigue (less pronounced than with benzodiazepines) [91-95], dizziness, and headache
[96,97]. Drug “hangover” and “withdrawal” effect has been reported with high doses [96]. Delirium, ameliorated by benzodiazepines,
indicated in one case report [98]. Some develop a “paradoxical reaction” leading to nervousness, and use for longer than 2 months
may result in insomnia [53]. Rare reports of hepatotoxicity with some preparations that include valerian [99] but may have been due to
other components. May interact with CNS depressants [91,92,100]. In cross-sectional survey (n = 1818), 15 cases of potential clinically
significant interactions with sedatives identified [37]. One case of SSRI use and valerian (with alcohol) indicated mental status changes
[101]
aBased on database searches of MEDLINE, EMBASE, PsychINFO, the Cochrane Library, CINAHL, NAPRALERT, MedEffect™ Canada, International Pharmaceutical Abstracts, CISCOM, and HerbMed for each NHP used in the
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the LOAELs (i.e., skin flushing, mild diarrhea) in a few
of the participants is relatively minor. Niacin intake ex-
cesses may be due to people receiving pharmacological
doses (i.e., 1 to 3 grams daily) to manage serum choles-
terol levels as per Canadian lipid guidelines [55]; at least
31 participants had high blood cholesterol levels. We
previously reported in this same sample that there was a
pattern of correlations between some nutrient intakes
(even above the ULs) and overall mental health based on
GAF scores [106], suggesting that these individuals may
have been benefiting from the additional nutrients. We
also note that the DRIs are based on healthy populations
and may have limited applicability to persons with men-
tal health conditions. For example, lithium in pharmaco-
logical doses would certainly be contraindicated in healthy
populations, but in individuals with bipolar disorder
higher amounts of this mineral are standard treatment.
While there was potential for more severe adverse reac-
tions from non-nutrient based NHPs, some of these prod-
ucts are also used as sources for conventional drugs [52].
The modest sample size may be interpreted as a limita-
tion. However, unlike the large population surveys on
NHP use, our study collected detailed data (e.g., types,
dose, frequency, nutrients from food plus supplements),
verified mental health diagnosis, and conducted an assess-
ment of potential for adverse events. The sample was com-
prised of mainly females, individuals with a mental health
condition that were generally high functioning, and resided
in an urban region which may limit the generalizability of
findings. In addition, it cannot be determined how well
MDABC membership reflects the population of all individ-
uals with mood disorders. The prevalence of NHP use in
this study may be overstated as the region in which the
data was collected is reported to have a higher propor-
tion of alternative medicine practices compared to other
Canadian provinces [10]. The prevalence estimate for po-
tential adverse effects may be conservative as data is lack-
ing about interactions of NHPs with each other and with
foods, and many surveillance systems are passive and con-
tain incomplete data (e.g., a specific dose level that led to
an adverse effect). Conversely, the potential for adverse
events may be overstated as the information obtained
tended to be based on anecdotal reports and not prospect-
ive data that specifically documents harms.Conclusions
Since NHP use among individuals with mood disorders
is prevalent, health care providers may best serve these
clients by becoming more knowledgeable about their
characteristics. Further research on the safety of NHPs
including their impact on the course and prognosis of
mental health conditions is also of relevance.Abbreviations
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